Table 2. Association of clinicopathologic variables with poor overall survival and with RARβ, MLH1, DLEC1, RASSF1A and BLU promoter methylation in the cohort of 239 NSCLC patients.

	Kaplan– Meier log-rank	RARβ methylation			hMLH1 methylation			DLEC1 methylation			RASSF1A methylation			BLU methylation
		No. of patients			No. of patients			No. of patients			No. of patients			No. of patients
Clinicopathologic parameters	P-value	+a	−b	P-value	+	−	P-value	+	−	P-value	+	−	P-value	+	−	P-value
Age	0.5754
<68 (n=117)		63	54	0.4706	39	78	0.4032	49	68	0.3567	41	76	0.4371	34	83	0.0397
>68 (n=122)		60	62		47	75		44	78		37	85		51	71
Gender	0.1680
Male (n=155)		76	79	0.3068	57	98	0.7293	61	94	0.8488	49	106	0.6468	53	102	0.5475
Female (n=84)		47	37		29	55		32	52		29	55		32	52
Tumour differentiation	0.2864
Poor (n=103)		48	55	0.3388	44	59	0.3106	44	59	0.7712	35	68	0.3738	34	69	0.2847
Moderate (n=113)		65	48		35	78		41	72		37	76		41	72
Well (n=20)		9	11		6	14		7	13		4	16		10	10
Unknown (n=3)		1	2		1	2		1	2		2	1		0	3
Histologic type	0.5207
ADC (n=92)		56	36	0.0317	21	71	0.0047	29	63	0.0696	25	67	0.0008	42	50	0.0278
LCC (n=54)		20	34		22	32		19	35		29	25		17	37
SCC (n=92)		47	45		42	50		44	48		23	69		25	67
Primary tumour stage	0.1014
T1 (n=64)		31	33	0.8517	16	48	0.0995	17	47	0.0555	19	45	0.8406	22	42	0.7303
T2 (n=154)		81	73		62	92		66	88		52	102		57	97
T3 (n=21)		11	10		8	13		10	11		7	14		6	15
Regional lymph node status	<0.0001
N0 (n=174)		91	83	0.6728	54	120	0.0091	53	121	<0.0001	52	122	0.1378	68	106	0.0632
N1 (n=65)		32	33		32	33		40	25		26	39		17	48
AJCC staging	<0.0001
Stage I (n=153)		80	73	0.7341	46	107	0.0110	43	110	<0.0001	45	108	0.1562	62	91	0.0327
Stage II (n=86)		43	43		40	46		50	36		33	53		23	63
Total		123	116		86	153		93	146		78	161		85	154

^a+Indicates number of patients with a methylated tumour.

^b−Indicates number of patients with no methylation detected.